Document 0273
 DOCN  M9460273
 TI    Long-standing protection of macaques against cell-free HIV-2 with a
       HIV-2 iscom vaccine.
 DT    9408
 AU    Putkonen P; Bjorling E; Akerblom L; Thorstensson R; Lovgren K; Benthin
       L; Chiodi F; Morein B; Biberfeld G; Norrby E; et al; Department of
       Immunology, Swedish Institute for Infectious; Disease Control,
       Karolinska Institute, Uppsala.
 SO    J Acquir Immune Defic Syndr. 1994 Jun;7(6):551-9. Unique Identifier :
       AIDSLINE MED/94231459
 AB    We investigated the capacity of two immunostimulating-complex (iscom)
       formulations including inactivated native HIV-2 viral proteins and
       selected peptides to induce protective immunity against HIV-2 in a
       nonhuman primate. Four cynomolgus monkeys were first immunized with five
       i.m. injections of purified detergent-disrupted HIV-2 virions (total
       dose, 0.7 mg) in iscoms over a period of 16 months. At months 18 and 20,
       all four macaques were given booster immunizations with iscom-coupled
       V3-derived synthetic peptides representing a dominating neutralizing
       region of HIV-2 gp125. Two weeks after the final dose of vaccine, the
       four vaccinated animals, together with four controls, were challenged
       i.v. with 10 monkey infectious doses (MID50) of monkey-cell-grown
       homologous cell-free virus, HIV-2SBL-6669/H5. After the challenge, the
       four control animals became readily infected; however, three of four
       vaccinated animals were protected as shown by repeated negative virus
       isolations and negative polymerase chain reaction for viral DNA and by
       failure to transmit HIV-2 infection with whole blood and lymph node
       cells into naive cynomolgus macaques. One of three protected animals
       showed an anamnestic antibody response to a dominating antigenic site,
       indicating possible limited virus replication. The vaccine-protected
       monkeys were subsequently resistant to rechallenge infection at 12, 15,
       and 18 months after the first challenge, suggesting that a reasonable
       duration of protective immunity had been induced by the vaccine.
 DE    Amino Acid Sequence  Animal  *AIDS Vaccines/ADMINISTRATION & DOSAGE
       Blotting, Western  Disease Models, Animal  DNA, Viral/ANALYSIS
       Enzyme-Linked Immunosorbent Assay  HIV Antibodies/BIOSYNTHESIS  HIV
       Envelope Protein gp120/CHEMISTRY/IMMUNOLOGY  HIV Infections/*PREVENTION
       & CONTROL  HIV-2/GENETICS/*IMMUNOLOGY/ISOLATION & PURIF  Immunization,
       Secondary  Injections, Intramuscular  *ISCOMs/ADMINISTRATION & DOSAGE
       Lymph Nodes/CYTOLOGY/MICROBIOLOGY  Lymphocytes/MICROBIOLOGY  Macaca
       fascicularis  Molecular Sequence Data  Neutralization Tests  Peptide
       Fragments/CHEMISTRY/IMMUNOLOGY  Polymerase Chain Reaction  Support,
       Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).